Skip to main content

Urokinase Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 27, 2023.

Applies to urokinase: intravenous powder for injection.

Warning

If possible before you receive urokinase, tell your doctor if you have a brain tumor or aneurysm, hemophilia or other bleeding disorder, high blood pressure, or if you have recently had a stroke, brain or spinal surgery, or medical emergency requiring CPR (cardiopulmonary resuscitation).

In an emergency situation it may not be possible to tell your caregivers about your health conditions. Make sure any doctor caring for you afterward knows you have received this medicine.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Urokinase increases your risk of bleeding, which can be severe or life-threatening. Call your doctor or seek emergency medical attention if you have bleeding that will not stop. Bleeding may occur from a surgical incision, or from the skin where a needle was inserted during a blood test or while receiving injectable medication. You may also have bleeding on the inside of your body, such as in your stomach or intestines, kidneys or bladder, brain, or within the muscles.

Call your doctor at once if you have signs of bleeding inside your body, such as:

Some side effects may occur during or within 1 hour after the injection. Tell your caregiver right away if you feel chilled or feverish, nauseated, light-headed, or have chest tightness, back pain, trouble breathing, or fast heartbeats.

Also call your doctor at once if you have:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to urokinase: intravenous powder for injection.

General

The most common and severe adverse reaction was hemorrhage, with puncture site being the most frequent location.[Ref]

Hematologic

Very common (10% or more): Bleeding resulting in at least 5% decrease in hematocrit (36.9%)

Common (1% to 10%): Significant bleeding events requiring transfusion of greater than 2 units of blood

Frequency not reported: Hemorrhage, hematocrit decreased without clinically detectable hemorrhage, fatal hemorrhage, hematocrit decreased, thrombocytopenia[Ref]

Cardiovascular

Common (1% to 10%): Hematoma, artery dissection, embolism, cholesterol embolism

Rare (less than 0.1%): Vascular pseudoaneurysm

Frequency not reported: Thromboembolism, wound hemorrhage, hypotension, flushing, cyanosis, tachycardia, hypertension, myocardial infarction

Postmarketing reports: Cardiac arrest, reperfusion ventricular arrhythmias[Ref]

Gastrointestinal

Common (1% to 10%): Gastrointestinal hemorrhage, retroperitoneal hemorrhage

Frequency not reported: Gingival hemorrhage, retroperitoneal hematoma, nausea, vomiting, orolingual edema[Ref]

Nervous system

Common (1% to 10%): Stroke, intracranial hemorrhage

Frequency not reported: Fatal intracranial hemorrhage, intracranial hematoma, hemiplegia

Postmarketing reports: Cerebral embolism, cerebral vascular accident[Ref]

Other

Common (1% to 10%): Fever, chills

Frequency not reported: Substernal pain

Postmarketing reports: Chest pain[Ref]

Genitourinary

Common (1% to 10%): Urogenital hemorrhage

Rare (less than 0.1%): Macroscopic hematuria

Frequency not reported: Microscopic hematuria[Ref]

Musculoskeletal

Common (1% to 10%): Muscle hemorrhage

Frequency not reported: Back pain[Ref]

Immunologic

Uncommon (0.1% to 1%): Allergic reaction

Rare (less than 0.1%): Hypersensitivity reactions, anaphylaxis

Very rare (less than 0.01%): Fatal anaphylaxis[Ref]

Hepatic

Uncommon (0.1% to 1%): Intrahepatic hemorrhage

Frequency not reported: Transient increase in transaminases[Ref]

Renal

Uncommon (0.1% to 1%): Renal failure[Ref]

Respiratory

Frequency not reported: Epistaxis, pulmonary embolism, dyspnea, hypoxemia, bronchospasm, recurrent pulmonary embolism

Postmarketing reports: Pulmonary edema[Ref]

Dermatologic

Frequency not reported: Urticaria, rash, pruritus, diaphoresis[Ref]

Local

Frequency not reported: Puncture site hemorrhage, puncture site hematoma, infusion reactions[Ref]

Metabolic

Frequency not reported: Acidosis[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Kinlytic (urokinase). ImaRx Therapeutics, Inc. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.